

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1. **(Original)** A polypeptide comprising a region having the amino acid sequence from 1st to 162nd amino acid in the amino acid sequence shown in SEQ ID NO:1 in SEQUENCE LISTING or a region having the same amino acid sequence as said amino acid sequence from 1st to 162nd amino acid in the amino acid sequence shown in SEQ ID NO:1 except that 1 to 40 amino acid residue(s) is(are) substituted, deleted and/or inserted, which polypeptide has a binding ability to TRAF2.

2. **(Original)** The polypeptide according to claim 1, comprising said region having the amino acid sequence from 1st to 162nd amino acid in the amino acid sequence shown in SEQ ID NO:1 in SEQUENCE LISTING or a region having the same amino acid sequence as said amino acid sequence from 1st to 162nd amino acid in the amino acid sequence shown in SEQ ID NO:1 except that 1 to 33 amino acid residue(s) is(are) substituted, deleted and/or inserted.

3. **(Original)** The polypeptide according to claim 2, comprising a region having the same amino acid sequence as said amino acid sequence from 1st to 162nd amino acid in the amino acid sequence shown in SEQ ID NO:1 except that at least one amino acid selected from the group consisting of 1st, 2nd, 3rd, 20th, 26th, 28th, 32nd, 35th, 37th, 38th, 41st, 44th, 55th, 57th,

68th, 71st, 74th, 77th, 95th, 97th, 100th, 101st, 114th, 117th, 126th, 127th, 134th, 136th, 143rd, 145th, 147th, 156th, 157th and 158th amino acid(s) is(are) substituted and/or deleted, and/or 1 to 3 amino acid(s) each is(are) inserted into site(s) next to said at least one amino acid selected from said group.

4. **(Original)** The polypeptide according to claim 2, comprising said region having the amino acid sequence from 1st to 162nd amino acid in the amino acid sequence shown in SEQ ID NO:1 in SEQUENCE LISTING.

5. **(Original)** The polypeptide according to claim 2, having the same amino acid sequence as shown in SEQ ID NO:1 in SEQUENCE LISTING, or having the same amino acid sequence as shown in SEQ ID NO:1 except that at least one amino acid selected from the group consisting of 1st, 2nd, 3rd, 20th, 26th, 28th, 32nd, 35th, 37th, 38th, 41st, 44th, 55th, 57th, 68th, 71st, 74th, 77th, 95th, 97th, 100th, 101st, 114th, 117th, 126th, 127th, 134th, 136th, 143rd, 145th, 147th, 156th, 157th, 158th, 163rd, 165th, 168th, 169th, 170th, 171st, 172nd, 173rd, 177th and 184th amino acids is substituted and/or deleted, and/or 1 to 3 amino acid(s) each is(are) inserted into site(s) next to said at least one amino acid selected from said group, which polypeptide has a binding ability to TRAF2.

6. **(Original)** The polypeptide according to claim 5, having the amino acid sequence shown in SEQ ID NO:1 in SEQUENCE LISTING.

7. **(Original)** A polypeptide comprising a region having the amino acid sequence from 1st to 162nd amino acid in the amino acid sequence shown in SEQ ID NO:3 in SEQUENCE LISTING or a region having the same amino acid sequence as said amino acid sequence from 1st to 162nd amino acid in the amino acid sequence shown in SEQ ID NO:3 except that 1 to 40 amino acid residue(s) is(are) substituted, deleted and/or inserted, which polypeptide has a binding ability to TRAF2.

8. **(Original)** The polypeptide according to claim 7, comprising said region having the amino acid sequence from 1st to 162nd amino acid in the amino acid sequence shown in SEQ ID NO:3 in SEQUENCE LISTING or a region having the same amino acid sequence as said amino acid sequence from 1st to 162nd amino acid in the amino acid sequence shown in SEQ ID NO:3 except that 1 to 33 amino acid residues is(are) substituted, deleted and/or inserted.

9. **(Original)** The polypeptide according to claim 8, comprising a region having the same amino acid sequence as said amino acid sequence from 1st to 162nd amino acid in the amino acid sequence shown in SEQ ID NO:3 except that at least one amino acid selected from the group consisting of 1st, 2nd, 3rd, 20th, 27th, 31st, 34th, 36th, 37th, 38th, 41st, 44th, 55th, 57th, 68th, 71st, 74th, 77th, 95th, 97th, 100th, 101st, 114th, 117th, 126th, 127th, 134th, 136th, 143rd, 145th, 147th, 156th, 157th and 158th amino acid(s) is(are) substituted and/or deleted, and/or 1 to 3 amino acid(s) each is(are) inserted into site(s) next to said at least one amino acid selected from said group.

10. **(Original)** The polypeptide according to claim 8, comprising said region having the amino acid sequence from 1st to 162nd amino acid in the amino acid sequence shown in SEQ ID NO:3 in SEQUENCE LISTING.

11. **(Original)** The polypeptide according to claim 8, having the same amino acid sequence as shown in SEQ ID NO:3 in SEQUENCE LISTING, or having the same amino acid sequence as shown in SEQ ID NO:3 except that at least one amino acid selected from the group consisting of 1st, 2nd, 3rd, 20th, 27th, 31st, 34th, 36th, 37th, 38th, 41st, 44th, 55th, 57th, 68th, 71st, 74th, 77th, 95th, 97th, 100th, 101st, 114th, 117th, 126th, 127th, 134th, 136th, 143rd, 145th, 147th, 156th, 157th, 158th, 163rd, 165th, 168th, 169th, 170th, 171st, 172nd, 173rd, 177th and 184th amino acid(s) is(are) substituted and/or deleted, and/or 1 to 3 amino acid(s) each is(are) inserted into site(s) next to said at least one amino acid selected from said group and/or into site between 25th and 26th amino acids.

12. **(Original)** The polypeptide according to claim 11, having the amino acid sequence shown in SEQ ID NO:3 in SEQUENCE LISTING.

13. **(Original)** A polypeptide comprising a region having the amino acid sequence from 1st to 162nd amino acid in the amino acid sequence shown in SEQ ID NO:1 or SEQ ID NO:3 in SEQUENCE LISTING or a region having a homology of not less than 70% with said amino acid sequence of said region, which polypeptide has a binding ability to TRAF2.

14. **(Original)** The polypeptide according to claim 13, wherein said homology is not less than 80%.

15. **(Original)** A polypeptide having an amino acid sequence with a homology of not less than 70% with the amino acid sequence shown in SEQ ID NO:1 or SEQ ID NO:3 in SEQUENCE LISTING.

16. **(Original)** The polypeptide according to claim 15, wherein said homology is not less than 78%.

17. **(Currently Amended)** A nucleic acid coding for said polypeptide according to ~~any one of claims 1 to 16.~~ claim 1, 7, 13 or 15.

18. **(Original)** The nucleic acid according to claim 17, having the nucleotide sequence shown in SEQ ID NO:2 or SEQ ID NO:4 in SEQUENCE LISTING or a nucleic acid which hybridizes with a nucleic acid complementary to said nucleic acid having the nucleotide sequence shown in SEQ ID NO:2 or SEQ ID NO:4 under stringent conditions.

19. **(Currently Amended)** An expression vector containing said nucleic acid according to ~~claim 17 or 18,~~ claim 17, which can express said nucleic acid in a host cell.

20. **(Currently Amended)** A cell into which said nucleic acid according to ~~claim 17 or 18~~ claim 17 is introduced, which expresses said ~~polypeptide according to any one of claims 1 to 16~~ polypeptide.

21. **(Currently Amended)** A nucleic acid which hybridizes with said nucleic acid according to ~~claim 17 or 18~~, claim 17, which can be used for detection of said nucleic acid, ~~acid according to claim 17 or 18~~.

22. **(Currently Amended)** The nucleic acid according to claim 21, which hybridizes with said nucleic acid having the nucleotide sequence shown in SEQ ID NO:2 or SEQ ID NO:4 in SEQUENCE LISTING.

23. **(Currently Amended)** The nucleic acid according to ~~claim 21 or 22~~, claim 21, which is a primer or a probe.

24. **(Currently Amended)** The nucleic acid according to ~~any one of claims 21 to 23~~, claim 21, comprising not less than 15 bases.

25. **(Currently Amended)** A method for measuring ~~said a~~ nucleic acid ~~according to claim 18~~, comprising contacting said probe according to claim 23 with said nucleic acid ~~according to claim 18~~ so as to hybridize them, and measuring the hybridized nucleic acid.

26. **(Currently Amended)** A method for measuring said ~~a~~ nucleic acid ~~according to claim 18~~, comprising carrying out a nucleic acid-amplification method using a pair of primers according to claim 23 as primers and using said nucleic acid ~~according to claim 18~~ as a template, and measuring amplified product.